Mycovia publishes positive new clinical results evaluating Vivjoa


Emerging US biopharmaceutical company Mycovia Pharmaceuticals has released top-line results from the evaluation of Vivjoa (oteseconazole) capsules in patients with recurrent vulvovaginal candidiasis (RVVC).

RVVC, also known as chronic yeast infection, is a distinct condition from vulvovaginal candidiasis (VVC) and is defined by the Centers for Disease Control and Prevention as three or more symptomatic episodes of yeast infection in 12 months.

The violet…

This article is available to registered users, to continue reading please register for free. A free trial gives you one-week access to exclusive features, interviews, recaps and commentary from the brightest minds in pharma and biotechnology. If you are already a registered user, please log in. If your trial has expired, you can subscribe here.

Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analysis and commentary from our global network of life science reporters.
• Receive The Pharma Letter daily news bulletin, free forever.

become a subscriber

• Unrestricted access to industry-leading pharma and biotech news, commentary and analysis.
• Updates on clinical trials, conferences, mergers and acquisitions, licensing, financing, regulation, patents and law, executive appointments, business strategy and financial results.
• Daily summary of important events in pharma and biotech.
• Monthly in-depth briefings on board meetings and M&A news.
• Choose from an affordable annual package or a flexible monthly subscription.


Comments are closed.